{
    "info": {
        "nct_id": "NCT04179032",
        "official_title": "A Multi-Center, Open-Label Trial to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Subcutaneously Administered Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Participants With Systemic Lupus Erythematosus (SLE)",
        "inclusion_criteria": "* Participant must be between 5 and 17 years of age inclusive, at the time of Day 1.\n* Participants who meet the 1997 American College of Rheumatology (ACR) criteria for the classification of SLE;\n\n  * Have or have had in series 4 or more of the 11 ACR criteria for the classification of SLE.\n* Have active SLE disease defined as a safety of estrogen in lupus erythematosus national assessment (SELENA) systemic lupus erythematosus disease activity index (SLEDAI) score >=6 at screening.\n* Have documented positive autoantibody test results within the study screening period, defined as an anti-nuclear antibody (ANA) titre >= 1:80 and/or a positive anti-dsDNA (>=30 international units per milliliter [IU/mL]) serum antibody test based on either the study's central laboratory results or the local laboratory results. Only unequivocally positive values as defined in the laboratory's reference range are acceptable; borderline values will not be accepted\n* Are on a stable SLE treatment regimen, \"Stable treatment at Baseline\" consists of any of the following medications (alone or in combination) administered for a period of at least 30 days prior to Day 1;\n\n  * Corticosteroids [prednisone or prednisone equivalent up to 0.5 milligram per kilogram per day (mg/kg/day)], for those participants on alternating day doses of steroids, use the average of 2 daily doses to calculate the average daily steroid dose.\n  * Other immunosuppressive or immunomodulatory agents including methotrexate, azathioprine, leflunomide, mycophenolate (including mycophenolate mofetil, mycophenolate mofetil hydrochloride, and mycophenolate sodium), calcineurin inhibitors (e.g. tacrolimus, cyclosporine), sirolimus, oral cyclophosphamide, 6-mercaptopurine or thalidomide.\n  * Anti-malarials (e.g. hydroxychloroquine, chloroquine, quinacrine).\n  * Non-steroidal anti-inflammatory drugs (NSAIDs)\n  * New SLE therapy must not be added within 30 days of Day 1.\n* Body weight >=15 kg.\n* Male and/or female;\n\n  * Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n  * No contraceptive measures are required for male participants.\n  * A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies, Is not a woman of childbearing potential (WOCBP) or Is a WOCBP and is using a contraceptive method that is highly effective, with a failure rate of <1%, during the belimumab treatment period and for at least 16 weeks, corresponding to the time needed to eliminate any study intervention(s) (e.g., 5 terminal half-lives), after the last dose of study intervention. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.\n  * A WOCBP must have a negative highly sensitive pregnancy test (serum or as required by local regulations) within 35 days before the first dose of belimumab.\n  * The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.\n* Participant signs and dates a written age appropriate assent form (in accordance with applicable regulations) and the parent or legal guardian (or emancipated minor) that has the ability to understand the requirements of the study, provides written informed consent (including consent for the use and disclosure of research-related health information) that the participant will comply with the study protocol procedures (including required study visits).\nHealthy volunteers allowed\nMust have minimum age of 5 Years\nMust have maximum age of 17 Years",
        "exclusion_criteria": "* Have an estimated glomerular filtration rate (eGFR) as calculated by Schwartz Formula of less than 30 milliliter/minute (mL/min).\n* Have acute severe nephritis defined as significant renal disease (e.g., the presence of urinary sediments and other laboratory abnormalities) that, in the opinion of the study investigator, may lead to the participant requiring induction therapy during the first 12 weeks of the trial.\n* Have a history of a major organ transplant (e.g., heart, lung, kidney, liver) or hematopoetic stem cell/marrow transplant.\n* Have clinical evidence of significant, unstable or uncontrolled, acute or chronic diseases not due to SLE (i.e., cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, renal, neurological, malignancy or infectious diseases) which, in the opinion of the investigator, could confound the results of the study or put the participant at undue risk.\n* Have a planned surgical procedure or a history of any other medical disease (e.g., cardiopulmonary), laboratory abnormality, or condition (e.g., poor venous access) that, in the opinion of the investigator, makes the participant unsuitable for the study.\n* Have a history of malignant neoplasm within the last 5 years.\n* Have evidence of serious suicide risk including any history of suicidal behavior in the last 6 months, or who in the investigator's opinion, pose a significant suicide risk.\n* Have a history of a primary immunodeficiency.\n* Have an immunoglobulin A (IgA) deficiency (IgA level <10 milligrams per deciliter [mg/dL]).\n* Have acute or chronic infections requiring management, as follows;\n\n  * Currently on any suppressive therapy for a chronic infection (such as tuberculosis, pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster and atypical mycobacteria).\n  * Use of parenteral [IV or Intramuscular (IM)] antibiotics (antibacterials, antivirals, anti-fungals, or anti parasitic agents) for infection within 60 days of Day 1.\n* Have a Grade 3 or greater laboratory abnormality based on the protocol defined adverse event and laboratory value severity grade scale except for the following that are allowed;\n\n  * Stable Grade 3 prothrombin time (PT) secondary to warfarin treatment.\n  * Stable Grade 3 partial thromboplastin time (PTT) due to lupus anticoagulant and not related to liver disease or anti-coagulant therapy.\n  * Stable Grade 3 hypoalbuminemia due to lupus nephritis, and not related to liver disease or malnutrition.\n  * Any grade proteinuria.\n  * Stable Grade 3 gamma glutamyl transferase (GGT) elevation due to lupus hepatitis, and not related to alcoholic liver disease, uncontrolled diabetes or viral hepatitis. If present, any abnormalities in the alanine amininotransferase (ALT) and or aspartate aminotransferase (AST) must be <= Grade 2.\n  * Stable Grade 3 neutropenia; or stable Grade 3 lymphopenia; or stable Grade 3 leukopenia, due to SLE.\n* Have a history of an anaphylactic reaction to parenteral administration of contrast agents, human or murine proteins or monoclonal antibodies.\n* Have ever received treatment with belimumab.\n* Have received any of the following within 364 days of Day 1;\n\n  * Treatment with any B-cell targeted therapy [e.g., rituximab, other anti-CD20 agents, anti-CD22 [epratuzumab], anti-CD52 [alemtuzumab], B lymphocyte stimulator (BLyS)-receptor fusion protein [BR3], transmembrane activator attached to the Fc portion of an immunoglobulin [TACI Fc]).\n  * Abatacept.\n  * Any biologic investigational agent.\n* Have required 3 or more courses of systemic corticosteroids for concomitant conditions (e.g., asthma, atopic dermatitis) within 90 days of Day 1 (topical or inhaled steroids are permitted).\n* Have received any of the following within 90 days of Day 1;\n\n  * Anti-tumor necrosis factor (TNF) therapy (e.g., adalimumab, etanercept, infliximab).\n  * Interleukin-1 receptor antagonist (anakinra).\n  * Intravenous immunoglobulin (IVIG).\n  * Plasmapheresis.\n* Have received any of the following within 30 days of Day 1;\n\n  * IV cyclophosphamide.\n  * A non-biologic investigational agent (30 day window or 5 half-lives, whichever is greater).\n  * Any new immunosuppressive/immunomodulatory agent.\n  * High dose prednisone or equivalent (>1.5 mg/kg/day) or any intramuscular or intravenous steroid injection.\n* Have received a live or live-attenuated vaccine within 30 days of Day 1.\n* Have active central nervous system (CNS) lupus (including seizures, psychosis, organic brain syndrome, cerebrovascular accident [CVA], cerebritis or CNS vasculitis) requiring therapeutic intervention within 60 days of Day 1.\n* Have required renal replacement therapy (e.g. hemodialysis, peritoneal dialysis) within 90 days of Day 1 or are currently on renal replacement therapy.\n* Participation in an interventional clinical study either concurrently or within 6 months of screening. Participation in an observational study may be permitted.\n* Positive immunodeficiency virus (HIV) antibody test\n* Hepatitis B: Serologic evidence of Hepatitis B (HB) infection defined as Hepatitis B surface antigen positive (HBsAg+) or Hepatitis B core antibody positive (HBcAb+)\n* Hepatitis C: Positive test for Hepatitis C antibody confirmed on an additional blood sample by ribonucleic acid (RNA) polymerase chain reaction (PCR) assay. Participants who are positive for Hepatitis C antibody and negative when the Hepatitis C RNA-PCR assay is performed on an additional sample will be eligible to participate. Participants who are positive for Hepatitis C antibody and have a positive result for the Hepatitis C virus (HCV) when the Hepatitis C RNA PCR assay is performed on the additional sample will not be eligible to participate. (Institution or country specific guidelines for blood sample volume limits must be followed in collection of the additional blood sample).\n* Have current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or dependence within 364 days prior to Day 1.\n* Are unable or unlikely, in the opinion of the investigator, to administer belimumab by SC injection and have no reliable source to administer the injection\n* Children in Care: A Child in Care (CiC) is a child who has been placed under the control or protection of an agency, organization, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation. The definition of a CiC can include a child cared for by foster parents or living in a care home or institution, provided that the arrangement falls within the definition above. The determination of whether a child meets the definition of CiC should be made with the study centre staff in consultation with the responsible institutional review board (IRB)/Ethics Committee.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.",
            "criterions": [
                {
                    "exact_snippets": "Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.",
                    "criterion": "contraceptive use",
                    "requirements": [
                        {
                            "requirement_type": "consistency with local regulations",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.",
            "criterions": [
                {
                    "exact_snippets": "review of medical history",
                    "criterion": "medical history",
                    "requirements": [
                        {
                            "requirement_type": "reviewed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "review of ... menstrual history",
                    "criterion": "menstrual history",
                    "requirements": [
                        {
                            "requirement_type": "reviewed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "review of ... recent sexual activity",
                    "criterion": "recent sexual activity",
                    "requirements": [
                        {
                            "requirement_type": "reviewed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "decrease the risk for inclusion of a woman with an early undetected pregnancy",
                    "criterion": "early undetected pregnancy",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 17 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 17 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 17,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have or have had in series 4 or more of the 11 ACR criteria for the classification of SLE.",
            "criterions": [
                {
                    "exact_snippets": "Have or have had in series 4 or more of the 11 ACR criteria for the classification of SLE",
                    "criterion": "ACR criteria for the classification of SLE",
                    "requirements": [
                        {
                            "requirement_type": "number of criteria met",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "criteria"
                            }
                        },
                        {
                            "requirement_type": "criteria set",
                            "expected_value": "11 ACR criteria for SLE"
                        },
                        {
                            "requirement_type": "temporal",
                            "expected_value": "in series (over time), current or past"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant signs and dates a written age appropriate assent form (in accordance with applicable regulations) and the parent or legal guardian (or emancipated minor) that has the ability to understand the requirements of the study, provides written informed consent (including consent for the use and disclosure of research-related health information) that the participant will comply with the study protocol procedures (including required study visits).",
            "criterions": [
                {
                    "exact_snippets": "Participant signs and dates a written age appropriate assent form",
                    "criterion": "assent form",
                    "requirements": [
                        {
                            "requirement_type": "signed and dated",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "age appropriateness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "parent or legal guardian (or emancipated minor) that has the ability to understand the requirements of the study, provides written informed consent (including consent for the use and disclosure of research-related health information)",
                    "criterion": "informed consent by parent/legal guardian/emancipated minor",
                    "requirements": [
                        {
                            "requirement_type": "provided",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability to understand study requirements",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "participant will comply with the study protocol procedures (including required study visits)",
                    "criterion": "compliance with study protocol procedures",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have documented positive autoantibody test results within the study screening period, defined as an anti-nuclear antibody (ANA) titre >= 1:80 and/or a positive anti-dsDNA (>=30 international units per milliliter [IU/mL]) serum antibody test based on either the study's central laboratory results or the local laboratory results. Only unequivocally positive values as defined in the laboratory's reference range are acceptable; borderline values will not be accepted",
            "criterions": [
                {
                    "exact_snippets": "documented positive autoantibody test results within the study screening period",
                    "criterion": "autoantibody test result",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": "within the study screening period"
                        }
                    ]
                },
                {
                    "exact_snippets": "anti-nuclear antibody (ANA) titre >= 1:80",
                    "criterion": "anti-nuclear antibody (ANA) titre",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "80 (titre)"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "positive anti-dsDNA (>=30 international units per milliliter [IU/mL]) serum antibody test",
                    "criterion": "anti-dsDNA serum antibody test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "IU/mL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "based on either the study's central laboratory results or the local laboratory results",
                    "criterion": "laboratory source for antibody test",
                    "requirements": [
                        {
                            "requirement_type": "source",
                            "expected_value": [
                                "study's central laboratory",
                                "local laboratory"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Only unequivocally positive values as defined in the laboratory's reference range are acceptable; borderline values will not be accepted",
                    "criterion": "antibody test result interpretation",
                    "requirements": [
                        {
                            "requirement_type": "result clarity",
                            "expected_value": "unequivocally positive"
                        },
                        {
                            "requirement_type": "borderline values",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* New SLE therapy must not be added within 30 days of Day 1.",
            "criterions": [
                {
                    "exact_snippets": "New SLE therapy must not be added within 30 days of Day 1.",
                    "criterion": "new SLE therapy",
                    "requirements": [
                        {
                            "requirement_type": "addition within 30 days of Day 1",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies, Is not a woman of childbearing potential (WOCBP) or Is a WOCBP and is using a contraceptive method that is highly effective, with a failure rate of <1%, during the belimumab treatment period and for at least 16 weeks, corresponding to the time needed to eliminate any study intervention(s) (e.g., 5 terminal half-lives), after the last dose of study intervention. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.",
            "criterions": [
                {
                    "exact_snippets": "female participant",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                },
                {
                    "exact_snippets": "not pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "not ... breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "breastfeeding",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Is not a woman of childbearing potential (WOCBP)",
                    "criterion": "woman of childbearing potential status",
                    "requirements": [
                        {
                            "requirement_type": "WOCBP",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Is a WOCBP and is using a contraceptive method that is highly effective, with a failure rate of <1%, during the belimumab treatment period and for at least 16 weeks, corresponding to the time needed to eliminate any study intervention(s) (e.g., 5 terminal half-lives), after the last dose of study intervention.",
                    "criterion": "contraceptive use in WOCBP",
                    "requirements": [
                        {
                            "requirement_type": "WOCBP",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraceptive method effectiveness",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "% failure rate"
                            }
                        },
                        {
                            "requirement_type": "contraceptive use duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 16,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants who meet the 1997 American College of Rheumatology (ACR) criteria for the classification of SLE;",
            "criterions": [
                {
                    "exact_snippets": "meet the 1997 American College of Rheumatology (ACR) criteria for the classification of SLE",
                    "criterion": "systemic lupus erythematosus (SLE) classification by 1997 ACR criteria",
                    "requirements": [
                        {
                            "requirement_type": "diagnostic criteria met",
                            "expected_value": "1997 ACR SLE classification criteria"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must be between 5 and 17 years of age inclusive, at the time of Day 1.",
            "criterions": [
                {
                    "exact_snippets": "Participant must be between 5 and 17 years of age inclusive",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 17,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Other immunosuppressive or immunomodulatory agents including methotrexate, azathioprine, leflunomide, mycophenolate (including mycophenolate mofetil, mycophenolate mofetil hydrochloride, and mycophenolate sodium), calcineurin inhibitors (e.g. tacrolimus, cyclosporine), sirolimus, oral cyclophosphamide, 6-mercaptopurine or thalidomide.",
            "criterions": [
                {
                    "exact_snippets": "Other immunosuppressive or immunomodulatory agents including methotrexate, azathioprine, leflunomide, mycophenolate (including mycophenolate mofetil, mycophenolate mofetil hydrochloride, and mycophenolate sodium), calcineurin inhibitors (e.g. tacrolimus, cyclosporine), sirolimus, oral cyclophosphamide, 6-mercaptopurine or thalidomide.",
                    "criterion": "use of immunosuppressive or immunomodulatory agents",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "agent_list",
                            "expected_value": [
                                "methotrexate",
                                "azathioprine",
                                "leflunomide",
                                "mycophenolate",
                                "mycophenolate mofetil",
                                "mycophenolate mofetil hydrochloride",
                                "mycophenolate sodium",
                                "calcineurin inhibitors",
                                "tacrolimus",
                                "cyclosporine",
                                "sirolimus",
                                "oral cyclophosphamide",
                                "6-mercaptopurine",
                                "thalidomide"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Are on a stable SLE treatment regimen, \"Stable treatment at Baseline\" consists of any of the following medications (alone or in combination) administered for a period of at least 30 days prior to Day 1;",
            "criterions": [
                {
                    "exact_snippets": "Are on a stable SLE treatment regimen, \"Stable treatment at Baseline\" ... administered for a period of at least 30 days prior to Day 1;",
                    "criterion": "SLE treatment regimen",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to Day 1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male and/or female;",
            "criterions": [
                {
                    "exact_snippets": "Male and/or female",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Non-steroidal anti-inflammatory drugs (NSAIDs)",
            "criterions": [
                {
                    "exact_snippets": "Non-steroidal anti-inflammatory drugs (NSAIDs)",
                    "criterion": "non-steroidal anti-inflammatory drug (NSAID) use",
                    "requirements": [
                        {
                            "requirement_type": "use/presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Anti-malarials (e.g. hydroxychloroquine, chloroquine, quinacrine).",
            "criterions": [
                {
                    "exact_snippets": "Anti-malarials (e.g. hydroxychloroquine, chloroquine, quinacrine)",
                    "criterion": "anti-malarial medication use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No contraceptive measures are required for male participants.",
            "criterions": [
                {
                    "exact_snippets": "No contraceptive measures are required for male participants.",
                    "criterion": "contraceptive measures for male participants",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Body weight >=15 kg.",
            "criterions": [
                {
                    "exact_snippets": "Body weight >=15 kg",
                    "criterion": "body weight",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 15,
                                "unit": "kg"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Corticosteroids [prednisone or prednisone equivalent up to 0.5 milligram per kilogram per day (mg/kg/day)], for those participants on alternating day doses of steroids, use the average of 2 daily doses to calculate the average daily steroid dose.",
            "criterions": [
                {
                    "exact_snippets": "Corticosteroids [prednisone or prednisone equivalent up to 0.5 milligram per kilogram per day (mg/kg/day)]",
                    "criterion": "corticosteroid dose",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 0.5,
                                "unit": "mg/kg/day"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "for those participants on alternating day doses of steroids, use the average of 2 daily doses to calculate the average daily steroid dose",
                    "criterion": "steroid dosing schedule",
                    "requirements": [
                        {
                            "requirement_type": "dose calculation method",
                            "expected_value": "average of 2 daily doses for alternating day dosing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 5 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 5 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A WOCBP must have a negative highly sensitive pregnancy test (serum or as required by local regulations) within 35 days before the first dose of belimumab.",
            "criterions": [
                {
                    "exact_snippets": "A WOCBP must have a negative highly sensitive pregnancy test (serum or as required by local regulations) within 35 days before the first dose of belimumab.",
                    "criterion": "pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "test_type",
                            "expected_value": [
                                "highly sensitive pregnancy test",
                                "serum or as required by local regulations"
                            ]
                        },
                        {
                            "requirement_type": "time_window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 35,
                                "unit": "days before first dose of belimumab"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Hepatitis C: Positive test for Hepatitis C antibody confirmed on an additional blood sample by ribonucleic acid (RNA) polymerase chain reaction (PCR) assay. Participants who are positive for Hepatitis C antibody and negative when the Hepatitis C RNA-PCR assay is performed on an additional sample will be eligible to participate. Participants who are positive for Hepatitis C antibody and have a positive result for the Hepatitis C virus (HCV) when the Hepatitis C RNA PCR assay is performed on the additional sample will not be eligible to participate. (Institution or country specific guidelines for blood sample volume limits must be followed in collection of the additional blood sample).",
            "criterions": [
                {
                    "exact_snippets": "Positive test for Hepatitis C antibody",
                    "criterion": "Hepatitis C antibody",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "confirmed on an additional blood sample by ribonucleic acid (RNA) polymerase chain reaction (PCR) assay ... Participants who are positive for Hepatitis C antibody and negative when the Hepatitis C RNA-PCR assay is performed on an additional sample will be eligible to participate.",
                    "criterion": "Hepatitis C RNA PCR assay result (on additional blood sample)",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants who are positive for Hepatitis C antibody and have a positive result for the Hepatitis C virus (HCV) when the Hepatitis C RNA PCR assay is performed on the additional sample will not be eligible to participate.",
                    "criterion": "Hepatitis C RNA PCR assay result (on additional blood sample)",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "positive (exclusion)"
                        }
                    ]
                },
                {
                    "exact_snippets": "Institution or country specific guidelines for blood sample volume limits must be followed in collection of the additional blood sample",
                    "criterion": "blood sample volume limits (for additional sample)",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": "institution or country specific guidelines"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have a history of a major organ transplant (e.g., heart, lung, kidney, liver) or hematopoetic stem cell/marrow transplant.",
            "criterions": [
                {
                    "exact_snippets": "history of a major organ transplant (e.g., heart, lung, kidney, liver)",
                    "criterion": "major organ transplant history",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hematopoetic stem cell/marrow transplant",
                    "criterion": "hematopoetic stem cell or marrow transplant history",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have an estimated glomerular filtration rate (eGFR) as calculated by Schwartz Formula of less than 30 milliliter/minute (mL/min).",
            "criterions": [
                {
                    "exact_snippets": "estimated glomerular filtration rate (eGFR) as calculated by Schwartz Formula of less than 30 milliliter/minute (mL/min)",
                    "criterion": "estimated glomerular filtration rate (eGFR)",
                    "requirements": [
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Schwartz Formula"
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have clinical evidence of significant, unstable or uncontrolled, acute or chronic diseases not due to SLE (i.e., cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, renal, neurological, malignancy or infectious diseases) which, in the opinion of the investigator, could confound the results of the study or put the participant at undue risk.",
            "criterions": [
                {
                    "exact_snippets": "clinical evidence of significant, unstable or uncontrolled, acute or chronic diseases not due to SLE (i.e., cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, renal, neurological, malignancy or infectious diseases)",
                    "criterion": "non-SLE diseases (cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, renal, neurological, malignancy, infectious)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "significant",
                                "unstable",
                                "uncontrolled"
                            ]
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": [
                                "acute",
                                "chronic"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have a history of malignant neoplasm within the last 5 years.",
            "criterions": [
                {
                    "exact_snippets": "history of malignant neoplasm within the last 5 years",
                    "criterion": "malignant neoplasm",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have acute severe nephritis defined as significant renal disease (e.g., the presence of urinary sediments and other laboratory abnormalities) that, in the opinion of the study investigator, may lead to the participant requiring induction therapy during the first 12 weeks of the trial.",
            "criterions": [
                {
                    "exact_snippets": "Have acute severe nephritis defined as significant renal disease (e.g., the presence of urinary sediments and other laboratory abnormalities)",
                    "criterion": "acute severe nephritis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "the presence of urinary sediments",
                    "criterion": "urinary sediments",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other laboratory abnormalities",
                    "criterion": "renal laboratory abnormalities",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "may lead to the participant requiring induction therapy during the first 12 weeks of the trial",
                    "criterion": "risk of requiring induction therapy within first 12 weeks",
                    "requirements": [
                        {
                            "requirement_type": "risk",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have a planned surgical procedure or a history of any other medical disease (e.g., cardiopulmonary), laboratory abnormality, or condition (e.g., poor venous access) that, in the opinion of the investigator, makes the participant unsuitable for the study.",
            "criterions": [
                {
                    "exact_snippets": "planned surgical procedure ... makes the participant unsuitable for the study",
                    "criterion": "planned surgical procedure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "suitability for study (per investigator opinion)",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "history of any other medical disease (e.g., cardiopulmonary) ... makes the participant unsuitable for the study",
                    "criterion": "history of other medical disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "suitability for study (per investigator opinion)",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "laboratory abnormality ... makes the participant unsuitable for the study",
                    "criterion": "laboratory abnormality",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "suitability for study (per investigator opinion)",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "condition (e.g., poor venous access) ... makes the participant unsuitable for the study",
                    "criterion": "other condition (e.g., poor venous access)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "suitability for study (per investigator opinion)",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have a history of a primary immunodeficiency.",
            "criterions": [
                {
                    "exact_snippets": "Have a history of a primary immunodeficiency",
                    "criterion": "primary immunodeficiency",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have evidence of serious suicide risk including any history of suicidal behavior in the last 6 months, or who in the investigator's opinion, pose a significant suicide risk.",
            "criterions": [
                {
                    "exact_snippets": "evidence of serious suicide risk",
                    "criterion": "serious suicide risk",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any history of suicidal behavior in the last 6 months",
                    "criterion": "history of suicidal behavior",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "who in the investigator's opinion, pose a significant suicide risk",
                    "criterion": "significant suicide risk (investigator's opinion)",
                    "requirements": [
                        {
                            "requirement_type": "investigator assessment",
                            "expected_value": "significant suicide risk"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Use of parenteral [IV or Intramuscular (IM)] antibiotics (antibacterials, antivirals, anti-fungals, or anti parasitic agents) for infection within 60 days of Day 1.",
            "criterions": [
                {
                    "exact_snippets": "Use of parenteral [IV or Intramuscular (IM)] antibiotics (antibacterials, antivirals, anti-fungals, or anti parasitic agents) for infection within 60 days of Day 1.",
                    "criterion": "parenteral antibiotic use for infection",
                    "requirements": [
                        {
                            "requirement_type": "route of administration",
                            "expected_value": [
                                "IV",
                                "Intramuscular (IM)"
                            ]
                        },
                        {
                            "requirement_type": "drug class",
                            "expected_value": [
                                "antibacterials",
                                "antivirals",
                                "anti-fungals",
                                "anti parasitic agents"
                            ]
                        },
                        {
                            "requirement_type": "indication",
                            "expected_value": "infection"
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 60,
                                "unit": "days before Day 1"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have received any of the following within 90 days of Day 1;",
            "criterions": [
                {
                    "exact_snippets": "Have received any of the following within 90 days of Day 1;",
                    "criterion": "receipt of specified treatments or interventions",
                    "requirements": [
                        {
                            "requirement_type": "time since receipt",
                            "expected_value": {
                                "operator": "<=",
                                "value": 90,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "receipt",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have a history of an anaphylactic reaction to parenteral administration of contrast agents, human or murine proteins or monoclonal antibodies.",
            "criterions": [
                {
                    "exact_snippets": "history of an anaphylactic reaction to parenteral administration of contrast agents",
                    "criterion": "anaphylactic reaction to parenteral contrast agents",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of an anaphylactic reaction to parenteral administration of ... human or murine proteins",
                    "criterion": "anaphylactic reaction to parenteral human or murine proteins",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of an anaphylactic reaction to parenteral administration of ... monoclonal antibodies",
                    "criterion": "anaphylactic reaction to parenteral monoclonal antibodies",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participation in an interventional clinical study either concurrently or within 6 months of screening. Participation in an observational study may be permitted.",
            "criterions": [
                {
                    "exact_snippets": "Participation in an interventional clinical study either concurrently or within 6 months of screening.",
                    "criterion": "participation in an interventional clinical study",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "=",
                                        "value": 1,
                                        "unit": "concurrent"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months since screening"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Participation in an observational study may be permitted.",
                    "criterion": "participation in an observational study",
                    "requirements": [
                        {
                            "requirement_type": "permitted",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any grade proteinuria.",
            "criterions": [
                {
                    "exact_snippets": "Any grade proteinuria",
                    "criterion": "proteinuria",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any biologic investigational agent.",
            "criterions": [
                {
                    "exact_snippets": "Any biologic investigational agent.",
                    "criterion": "biologic investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Positive immunodeficiency virus (HIV) antibody test",
            "criterions": [
                {
                    "exact_snippets": "Positive immunodeficiency virus (HIV) antibody test",
                    "criterion": "HIV antibody test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Interleukin-1 receptor antagonist (anakinra).",
            "criterions": [
                {
                    "exact_snippets": "Interleukin-1 receptor antagonist (anakinra)",
                    "criterion": "interleukin-1 receptor antagonist (anakinra)",
                    "requirements": [
                        {
                            "requirement_type": "exposure or use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* IV cyclophosphamide.",
            "criterions": [
                {
                    "exact_snippets": "IV cyclophosphamide",
                    "criterion": "cyclophosphamide administration route",
                    "requirements": [
                        {
                            "requirement_type": "route",
                            "expected_value": "intravenous"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any new immunosuppressive/immunomodulatory agent.",
            "criterions": [
                {
                    "exact_snippets": "Any new immunosuppressive/immunomodulatory agent",
                    "criterion": "immunosuppressive or immunomodulatory agent",
                    "requirements": [
                        {
                            "requirement_type": "new use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have a Grade 3 or greater laboratory abnormality based on the protocol defined adverse event and laboratory value severity grade scale except for the following that are allowed;",
            "criterions": [
                {
                    "exact_snippets": "Have a Grade 3 or greater laboratory abnormality based on the protocol defined adverse event and laboratory value severity grade scale",
                    "criterion": "laboratory abnormality",
                    "requirements": [
                        {
                            "requirement_type": "severity grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have ever received treatment with belimumab.",
            "criterions": [
                {
                    "exact_snippets": "Have ever received treatment with belimumab",
                    "criterion": "prior belimumab treatment",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Plasmapheresis.",
            "criterions": [
                {
                    "exact_snippets": "Plasmapheresis",
                    "criterion": "plasmapheresis",
                    "requirements": [
                        {
                            "requirement_type": "history or current use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Anti-tumor necrosis factor (TNF) therapy (e.g., adalimumab, etanercept, infliximab).",
            "criterions": [
                {
                    "exact_snippets": "Anti-tumor necrosis factor (TNF) therapy (e.g., adalimumab, etanercept, infliximab)",
                    "criterion": "anti-tumor necrosis factor (TNF) therapy",
                    "requirements": [
                        {
                            "requirement_type": "exposure/use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Stable Grade 3 partial thromboplastin time (PTT) due to lupus anticoagulant and not related to liver disease or anti-coagulant therapy.",
            "criterions": [
                {
                    "exact_snippets": "Stable Grade 3 partial thromboplastin time (PTT)",
                    "criterion": "partial thromboplastin time (PTT)",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": "Grade 3"
                        },
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "due to lupus anticoagulant",
                    "criterion": "cause of elevated PTT",
                    "requirements": [
                        {
                            "requirement_type": "cause",
                            "expected_value": "lupus anticoagulant"
                        }
                    ]
                },
                {
                    "exact_snippets": "not related to liver disease or anti-coagulant therapy",
                    "criterion": "cause of elevated PTT",
                    "requirements": [
                        {
                            "requirement_type": "not caused by",
                            "expected_value": [
                                "liver disease",
                                "anti-coagulant therapy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hepatitis B: Serologic evidence of Hepatitis B (HB) infection defined as Hepatitis B surface antigen positive (HBsAg+) or Hepatitis B core antibody positive (HBcAb+)",
            "criterions": [
                {
                    "exact_snippets": "Serologic evidence of Hepatitis B (HB) infection defined as Hepatitis B surface antigen positive (HBsAg+)",
                    "criterion": "Hepatitis B surface antigen",
                    "requirements": [
                        {
                            "requirement_type": "serologic status",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "Serologic evidence of Hepatitis B (HB) infection defined as ... Hepatitis B core antibody positive (HBcAb+)",
                    "criterion": "Hepatitis B core antibody",
                    "requirements": [
                        {
                            "requirement_type": "serologic status",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have acute or chronic infections requiring management, as follows;",
            "criterions": [
                {
                    "exact_snippets": "acute or chronic infections requiring management",
                    "criterion": "infections",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "acute",
                                "chronic"
                            ]
                        },
                        {
                            "requirement_type": "requirement for management",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A non-biologic investigational agent (30 day window or 5 half-lives, whichever is greater).",
            "criterions": [
                {
                    "exact_snippets": "A non-biologic investigational agent (30 day window or 5 half-lives, whichever is greater)",
                    "criterion": "non-biologic investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "exposure window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 30,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have required renal replacement therapy (e.g. hemodialysis, peritoneal dialysis) within 90 days of Day 1 or are currently on renal replacement therapy.",
            "criterions": [
                {
                    "exact_snippets": "Have required renal replacement therapy (e.g. hemodialysis, peritoneal dialysis) within 90 days of Day 1",
                    "criterion": "renal replacement therapy",
                    "requirements": [
                        {
                            "requirement_type": "history within timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 90,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "are currently on renal replacement therapy",
                    "criterion": "renal replacement therapy",
                    "requirements": [
                        {
                            "requirement_type": "current status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or dependence within 364 days prior to Day 1.",
            "criterions": [
                {
                    "exact_snippets": "Have current drug or alcohol abuse or dependence",
                    "criterion": "drug or alcohol abuse or dependence",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "current"
                        }
                    ]
                },
                {
                    "exact_snippets": "a history of drug or alcohol abuse or dependence within 364 days prior to Day 1",
                    "criterion": "drug or alcohol abuse or dependence",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 364,
                                        "unit": "days prior to Day 1"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with any B-cell targeted therapy [e.g., rituximab, other anti-CD20 agents, anti-CD22 [epratuzumab], anti-CD52 [alemtuzumab], B lymphocyte stimulator (BLyS)-receptor fusion protein [BR3], transmembrane activator attached to the Fc portion of an immunoglobulin [TACI Fc]).",
            "criterions": [
                {
                    "exact_snippets": "Treatment with any B-cell targeted therapy [e.g., rituximab, other anti-CD20 agents, anti-CD22 [epratuzumab], anti-CD52 [alemtuzumab], B lymphocyte stimulator (BLyS)-receptor fusion protein [BR3], transmembrane activator attached to the Fc portion of an immunoglobulin [TACI Fc])",
                    "criterion": "B-cell targeted therapy treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have an immunoglobulin A (IgA) deficiency (IgA level <10 milligrams per deciliter [mg/dL]).",
            "criterions": [
                {
                    "exact_snippets": "Have an immunoglobulin A (IgA) deficiency (IgA level <10 milligrams per deciliter [mg/dL])",
                    "criterion": "immunoglobulin A (IgA) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Stable Grade 3 prothrombin time (PT) secondary to warfarin treatment.",
            "criterions": [
                {
                    "exact_snippets": "Stable Grade 3 prothrombin time (PT)",
                    "criterion": "prothrombin time (PT)",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": "3"
                        },
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "secondary to warfarin treatment",
                    "criterion": "cause of prothrombin time (PT) abnormality",
                    "requirements": [
                        {
                            "requirement_type": "cause",
                            "expected_value": "warfarin treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Are unable or unlikely, in the opinion of the investigator, to administer belimumab by SC injection and have no reliable source to administer the injection",
            "criterions": [
                {
                    "exact_snippets": "Are unable or unlikely, in the opinion of the investigator, to administer belimumab by SC injection",
                    "criterion": "ability to self-administer belimumab by SC injection",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "have no reliable source to administer the injection",
                    "criterion": "reliable source to administer belimumab injection",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Abatacept.",
            "criterions": [
                {
                    "exact_snippets": "Abatacept.",
                    "criterion": "abatacept",
                    "requirements": [
                        {
                            "requirement_type": "exposure or use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have required 3 or more courses of systemic corticosteroids for concomitant conditions (e.g., asthma, atopic dermatitis) within 90 days of Day 1 (topical or inhaled steroids are permitted).",
            "criterions": [
                {
                    "exact_snippets": "Have required 3 or more courses of systemic corticosteroids for concomitant conditions (e.g., asthma, atopic dermatitis) within 90 days of Day 1",
                    "criterion": "systemic corticosteroid courses",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "courses"
                            }
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "within 90 days of Day 1"
                        }
                    ]
                },
                {
                    "exact_snippets": "topical or inhaled steroids are permitted",
                    "criterion": "topical or inhaled steroid use",
                    "requirements": [
                        {
                            "requirement_type": "permitted",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Intravenous immunoglobulin (IVIG).",
            "criterions": [
                {
                    "exact_snippets": "Intravenous immunoglobulin (IVIG)",
                    "criterion": "intravenous immunoglobulin (IVIG)",
                    "requirements": [
                        {
                            "requirement_type": "exposure or use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Stable Grade 3 hypoalbuminemia due to lupus nephritis, and not related to liver disease or malnutrition.",
            "criterions": [
                {
                    "exact_snippets": "Stable Grade 3 hypoalbuminemia",
                    "criterion": "hypoalbuminemia",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": "3"
                        },
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "due to lupus nephritis",
                    "criterion": "cause of hypoalbuminemia",
                    "requirements": [
                        {
                            "requirement_type": "cause",
                            "expected_value": "lupus nephritis"
                        }
                    ]
                },
                {
                    "exact_snippets": "not related to liver disease or malnutrition",
                    "criterion": "cause of hypoalbuminemia",
                    "requirements": [
                        {
                            "requirement_type": "not caused by",
                            "expected_value": [
                                "liver disease",
                                "malnutrition"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have received any of the following within 364 days of Day 1;",
            "criterions": [
                {
                    "exact_snippets": "Have received any of the following within 364 days of Day 1;",
                    "criterion": "receipt of specified treatments or interventions",
                    "requirements": [
                        {
                            "requirement_type": "time since receipt",
                            "expected_value": {
                                "operator": "<=",
                                "value": 364,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Currently on any suppressive therapy for a chronic infection (such as tuberculosis, pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster and atypical mycobacteria).",
            "criterions": [
                {
                    "exact_snippets": "Currently on any suppressive therapy for a chronic infection",
                    "criterion": "suppressive therapy for chronic infection",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic infection (such as tuberculosis, pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster and atypical mycobacteria)",
                    "criterion": "chronic infection type",
                    "requirements": [
                        {
                            "requirement_type": "infection type",
                            "expected_value": [
                                "tuberculosis",
                                "pneumocystis",
                                "cytomegalovirus",
                                "herpes simplex virus",
                                "herpes zoster",
                                "atypical mycobacteria"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Stable Grade 3 neutropenia; or stable Grade 3 lymphopenia; or stable Grade 3 leukopenia, due to SLE.",
            "criterions": [
                {
                    "exact_snippets": "Stable Grade 3 neutropenia",
                    "criterion": "neutropenia",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": "=",
                                "value": 3,
                                "unit": "N/A"
                            }
                        },
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "stable Grade 3 lymphopenia",
                    "criterion": "lymphopenia",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": "=",
                                "value": 3,
                                "unit": "N/A"
                            }
                        },
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "stable Grade 3 leukopenia, due to SLE",
                    "criterion": "leukopenia",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": "=",
                                "value": 3,
                                "unit": "N/A"
                            }
                        },
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "cause",
                            "expected_value": "SLE"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have received a live or live-attenuated vaccine within 30 days of Day 1.",
            "criterions": [
                {
                    "exact_snippets": "Have received a live or live-attenuated vaccine within 30 days of Day 1.",
                    "criterion": "live or live-attenuated vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Stable Grade 3 gamma glutamyl transferase (GGT) elevation due to lupus hepatitis, and not related to alcoholic liver disease, uncontrolled diabetes or viral hepatitis. If present, any abnormalities in the alanine amininotransferase (ALT) and or aspartate aminotransferase (AST) must be <= Grade 2.",
            "criterions": [
                {
                    "exact_snippets": "Stable Grade 3 gamma glutamyl transferase (GGT) elevation due to lupus hepatitis, and not related to alcoholic liver disease, uncontrolled diabetes or viral hepatitis.",
                    "criterion": "gamma glutamyl transferase (GGT) elevation",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": "=",
                                "value": 3,
                                "unit": "Grade"
                            }
                        },
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "cause",
                            "expected_value": "lupus hepatitis"
                        },
                        {
                            "requirement_type": "exclusion_cause",
                            "expected_value": [
                                "alcoholic liver disease",
                                "uncontrolled diabetes",
                                "viral hepatitis"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "If present, any abnormalities in the alanine amininotransferase (ALT) and or aspartate aminotransferase (AST) must be <= Grade 2.",
                    "criterion": "alanine aminotransferase (ALT) abnormality",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "Grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "If present, any abnormalities in the alanine amininotransferase (ALT) and or aspartate aminotransferase (AST) must be <= Grade 2.",
                    "criterion": "aspartate aminotransferase (AST) abnormality",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "Grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Children in Care: A Child in Care (CiC) is a child who has been placed under the control or protection of an agency, organization, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation. The definition of a CiC can include a child cared for by foster parents or living in a care home or institution, provided that the arrangement falls within the definition above. The determination of whether a child meets the definition of CiC should be made with the study centre staff in consultation with the responsible institutional review board (IRB)/Ethics Committee.",
            "criterions": [
                {
                    "exact_snippets": "A Child in Care (CiC) is a child who has been placed under the control or protection of an agency, organization, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation.",
                    "criterion": "Child in Care (CiC) status",
                    "requirements": [
                        {
                            "requirement_type": "placement_status",
                            "expected_value": "placed under the control or protection of an agency, organization, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation"
                        }
                    ]
                },
                {
                    "exact_snippets": "can include a child cared for by foster parents or living in a care home or institution, provided that the arrangement falls within the definition above.",
                    "criterion": "living arrangement",
                    "requirements": [
                        {
                            "requirement_type": "care_setting",
                            "expected_value": [
                                "cared for by foster parents",
                                "living in a care home",
                                "living in an institution"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "The determination of whether a child meets the definition of CiC should be made with the study centre staff in consultation with the responsible institutional review board (IRB)/Ethics Committee.",
                    "criterion": "CiC status determination process",
                    "requirements": [
                        {
                            "requirement_type": "determination_process",
                            "expected_value": "study centre staff in consultation with IRB/Ethics Committee"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* High dose prednisone or equivalent (>1.5 mg/kg/day) or any intramuscular or intravenous steroid injection.",
            "criterions": [
                {
                    "exact_snippets": "High dose prednisone or equivalent (>1.5 mg/kg/day)",
                    "criterion": "prednisone or equivalent steroid dose",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "mg/kg/day"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "any intramuscular or intravenous steroid injection",
                    "criterion": "intramuscular or intravenous steroid injection",
                    "requirements": [
                        {
                            "requirement_type": "administration route",
                            "expected_value": [
                                "intramuscular",
                                "intravenous"
                            ]
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have active central nervous system (CNS) lupus (including seizures, psychosis, organic brain syndrome, cerebrovascular accident [CVA], cerebritis or CNS vasculitis) requiring therapeutic intervention within 60 days of Day 1.",
            "criterions": [
                {
                    "exact_snippets": "active central nervous system (CNS) lupus",
                    "criterion": "central nervous system (CNS) lupus",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "(including seizures, psychosis, organic brain syndrome, cerebrovascular accident [CVA], cerebritis or CNS vasculitis)",
                    "criterion": "CNS manifestations (seizures, psychosis, organic brain syndrome, cerebrovascular accident [CVA], cerebritis, CNS vasculitis)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring therapeutic intervention within 60 days of Day 1",
                    "criterion": "therapeutic intervention for CNS lupus",
                    "requirements": [
                        {
                            "requirement_type": "time since intervention",
                            "expected_value": {
                                "operator": "<=",
                                "value": 60,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "necessity of intervention",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have received any of the following within 30 days of Day 1;",
            "criterions": [
                {
                    "exact_snippets": "Have received any of the following within 30 days of Day 1;",
                    "criterion": "receipt of specified treatments or interventions",
                    "requirements": [
                        {
                            "requirement_type": "time since receipt",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "receipt",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Have active SLE disease defined as a safety of estrogen in lupus erythematosus national assessment (SELENA) systemic lupus erythematosus disease activity index (SLEDAI) score >=6 at screening.",
            "criterions": [
                {
                    "exact_snippets": "Have active SLE disease defined as ... SLEDAI score >=6 at screening",
                    "criterion": "systemic lupus erythematosus (SLE) disease activity",
                    "requirements": [
                        {
                            "requirement_type": "activity index (SLEDAI) score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": ""
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at screening"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}